Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.

ABSTRACT:

Background and aims

This retrospective review of patients with recurrent glioblastoma treated at the Preston Robert Tisch Brain Tumor Center investigated treatment patterns, survival, and safety with bevacizumab in a real-world setting.

Methods

Adult patients with glioblastoma who initiated bevacizumab at disease progression between January 1, 2009, and May 14, 2012, were included. A Kaplan-Meier estimator was used to describe overall survival (OS), progression-free survival (PFS), and time to greater than or equal to 20% reduction in Karnofsky Performance Status (KPS). The effect of baseline demographic and clinical factors on survival was examined using a Cox proportional hazards model. Adverse event (AE) data were collected.

Results

Seventy-four patients, with a me

SUBMITTER: Desjardins A 

PROVIDER: S-EPMC6482327 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature